Parry MG, et al. - Researchers assessed the toxicity of intensity-modulated radiation therapy (IMRT) to the prostate and the pelvic lymph nodes (PPLN-IMRT) vs prostate-only IMRT (PO-IMRT) for treating high-risk prostate cancer. Using data from the Cancer Registry, the National Radiotherapy Dataset, and Hospital Episode Statistics, an administrative database of all hospital admissions, researchers identified patients with high-risk localized or locally advanced prostate cancer treated with IMRT in the English National Health Service between 2010 and 2013; 780 patients were identified who underwent the PPLN-IMRT and 3,065 patients were identified who underwent PO-IMRT. Incidence of GU toxicity was 9% and 8 %, respectively and incidence of GI toxicity was 14% for both groups. Observations revealed no increased GI or genitourinary toxicity at 3 years in correlation to the inclusion of pelvic lymph node in radiation fields for high-risk or locally advanced prostate cancer.